<DOC>
	<DOCNO>NCT00316407</DOCNO>
	<brief_summary>The purpose study determine effectiveness , safety , tolerability best dose Lapatinib ( GW572016 ) combination carboplatin paclitaxel .</brief_summary>
	<brief_title>Lapatinib/Carboplatin/Paclitaxel Previously Treated Ovarian Breast Cancer Patients</brief_title>
	<detailed_description>The MTD find phase I portion study oral lapatinib 1000 mg per day 4 week cycle paclitaxel 60 mg/m2 weekly x 3 4 week cycle carboplatin AUC 2 weekly x 3 4 week cycle .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Relapsed ( Stage III IV ) ovarian , primary peritoneal , fallopian tube carcinoma patient . Stage IV metastatic breast cancer patient fail four previous chemotherapy Stage IV disease . Ability swallow retain oral medication . Measurable disease Treatment previous weekly carboplatin paclitaxel . No prior treatment erbB target therapy erlotinib , gefitinib cetuximab . No concomitant requirement medication classification CYP3A4 inducer inhibitor .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>